BUZZ-Vera jumps on additional mid-stage study data for kidney disease drug

Reuters10-28

** Vera Therapeutics' shares rise 14.1% to $46.88, highest since April ** On Saturday, Vera reported additional data from a mid-stage study testing its kidney disease drug, atacicept, as a potential treatment for IgA nephropathy

** IgA nephropathy causes a protein called immunoglobulin A to build up in the kidney

** At week 96, atacicept helped in reducing excess levels of a protein in urine and stabilizing kidney function levels, compared to placebo - VERA ** VERA said it will submit results from late-stage study of atacicept in Q2 2025

** Including session's move, stock has more than tripled YTD

(Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment